1. "2017"
Formats
  1. Journal Article (3053)
  2. Meeting Abstract (1581)
  3. Book Section (242)
  4. Conference Paper (35)
  5. Book Whole (12)
  6. Editorial (1)
  7. Review (1)
Groups
  1. Department of Medicine (2037)
  2. GSK Faculty (1130)
  3. Solid Tumor Oncology Division (1105)
  4. Sloan Kettering Institute Postdocs (1022)
  5. Surgery (893)
  6. Survivorship Research (780)

More Groups

People
  1. Sergio Giralt (86)
  2. Jose Baselga (68)
  3. Michael Berger (67)
  4. Monica Morrow (65)
  5. Jedd Wolchok (62)
  6. Martin Tallman (61)

More People

Years
  1. 2017 (4925)
Publications
  1. Journal of Clinical Oncology (349)
  2. Blood (233)
  3. Annals of Oncology (123)
  4. International Journal of Radiation Oncology, Biology, Physics (122)
  5. Modern Pathology (85)
  6. Laboratory Investigation (76)

More Publications

Publishers
  1. Elsevier Inc. (599)
  2. Springer (383)
  3. American Society of Clinical Oncology (378)
  4. Nature Publishing Group (310)
  5. Oxford University Press (280)
  6. American Society of Hematology (246)

More Publishers

Results (4925)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Nrf2 is a critical mediator of CD4 T cell-induced acute graft-versus-host disease
    Meeting Abstract

    Tsai, J.; Velardi, E.; Shono, Y.; Argyropoulos, K.; Smith, O. M.; Lazrak, A.; Liu, C.; Murphy, G. F.; Fu, Y. Y.; Hanash, A. M.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Oncogenic mutations in XPO1 promote lymphoid transformation by altering nuclear/cytoplasmic localization of NFκB signaling intermediates
    Meeting Abstract

    Taylor, J.; Zhang, X. J.; Paffenholz, S. V.; Penson, A. V.; Chang, M.; Marcelus, C.; Bitner, L. E.; Chung, Y. R.; Yoshimi, A.; Lee, S. C. W.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Targeting PRMT1 as a novel curative therapy for acute myeloid leukemia
    Meeting Abstract

    Su, H.; Jin, S.; Shen, Y.; Kutny, M. A.; Jin, J.; Luo, M.; Zhao, X.
    Blood (2017)

    Fulltext@MSK | Save
  • Genetic profiling and deep IDH1 mutation clearance to ≤0.04% in ivosidenib (AG-120)-treated patients with mutant IDH1 relapsed or refractory and untreated AML
    Meeting Abstract

    Stone, R. M.; Choe, S.; Zhang, V.; Marteyn, B.; Penard-Lacronique, V.; Wang, H.; DiNardo, C. D.; Stein, E. M.; Fathi, A. T.; Tallman, M. S.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • The addition of midostaurin to standard chemotherapy decreases cumulative incidence of relapse (CIR) in the international prospective randomized, placebo-controlled, double-blind trial (CALGB 10603 / RATIFY [Alliance]) for newly diagnosed acute myeloid leukemia (AML) patients with FLT3 mutations
    Meeting Abstract

    Stone, R. M.; Mandrekar, S. J.; Sanford, B. L.; Laumann, K.; Geyer, S. M.; Bloomfield, C. D.; Dohner, K.; Thiede, C.; Marcucci, G.; Lo Coco, F.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Real world clinical and economic burden of patients with Hodgkin lymphoma (HL) who fail frontline (FL) therapy in the US
    Meeting Abstract

    Straus, D. J.; Bonafede, M.; Feliciano, J.; Cai, Q.; Noxon, V.; Princic, N.; Josephson, N.; Richhariya, A.
    Blood (2017)

    Fulltext@MSK | Save
  • Characterization of NTRK fusions and therapeutic response to NTRK inhibition in hematologic malignancies
    Meeting Abstract

    Taylor, J.; Marcelus, C.; Pavlick, D.; Benayed, R.; Yoshimi, A.; Cocco, E.; Durham, B. H.; Hechtman, J. F.; Chung, Y. R.; Mullaney, K.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Romiplostim for chemotherapy-induced thrombocytopenia (CIT). Results of a phase 2 trial
    Meeting Abstract

    Soff, G. A.; Miao, Y.; Devlin, S. M.; Mantha, S.; Mones, J. V.; Li, V. J.; Abou-Alfa, G. K.; Cercek, A.; Kemeny, N.; Parameswaran, R.
    Blood (2017)

    Fulltext@MSK | Save
  • Continuing enasidenib treatment for patients with mutant- IDH2 (m IDH2) relapsed or refractory acute myeloid leukemia (R/R AML) with stable disease may result in improved survival and responses over time
    Meeting Abstract

    Stein, E. M.; Stone, R. M.; Pollyea, D. A.; Roboz, G. J.; Altman, J. K.; DiNardo, C. D.; de Botton, S.; Tu, N.; Swern, A. S.; Tosolini, A.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • A validated risk model for overall survival in relapsed/refractory chronic lymphocytic leukemia applicable to patients treated with novel therapies and standard of care
    Meeting Abstract

    Soumerai, J. D.; Ni, A.; Darif, M.; Londhe, A.; Xing, G.; Huang, J.; Lin, M.; Byrd, J. C.; Chanan-Khan, A. A.; Furman, R. R.; more...
    Blood (2017)

    Fulltext@MSK | Save